Opendata, web and dolomites

OvaVAx SIGNED

100% Bacteria free eggs for use in production of human and animal vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OvaVAx project word cloud

Explore the words cloud of the OvaVAx project. It provides you a very rough idea of what is the project "OvaVAx" about.

specialist    fertilised    2021    manufacturing    specialises    globally    chicken    world    external    patent    superior    manufacture    skills    opportunity    industry    innovation    2022    services    demands    demand    contamination    standards    vaccines    market    pharmaceutical       led    viral    eliminate    service    team    supplier    leonard    seven    89bn    catherine    yields    vaccine    group    avian    pandemic    ovagen    immunisation    annually    benefits    dr    yield    lives    usd    eggs    health    ogl    utilising    ireland    quality    egg    gf    12    free    disruptive    biotechnology    commercially    agr    first    pull    caulfield    providers    expertise       pathogen    germ    ceo    protected    moran    worth    investors    cagr    manufacturers    1bn    entrepreneurs    invested    transgenics    whilst    rapid    servicing    considerable    exceptionally    populations    global    ltd    bacterial    enterprise    good    spf    contract    coo    industries    vc    founders    serial    91m    size    company    protect    innovative    48bn    biopharma    vision   

Project "OvaVAx" data sheet

The following table provides information about the project.

Coordinator
OVAGEN GROUP LIMITED 

Organization address
address: CARRENTRILA
city: BALLINA
postcode: F26PC79
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙366˙875 €
 EC max contribution 2˙356˙812 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OVAGEN GROUP LIMITED IE (BALLINA) coordinator 2˙356˙812.00

Map

 Project objective

Disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. Ovagen Group Ltd. (OGL) is an innovation-based biotechnology company, led by serial entrepreneurs, providing specialist contract services to Biopharma, Pharmaceutical and Vaccine industries. OGL specialises in avian Germ-Free (GF) technology and avian transgenics to Good Manufacturing Practice standards. The company’s vision is to be the go-to supplier of superior quality GF eggs to the vaccine industry globally by 2021.

INNOVATION: The founders Dr Leonard Moran CEO and Dr Catherine Caulfield COO together with external VC investors and Enterprise Ireland have invested €12.91M in seven years of R&D, utilising the considerable skills, expertise and experience of our team within this field to develop a unique and novel, patent protected process to enable commercially viable production of the World’s first germ-free (GF) eggs, to eliminate bacterial contamination through eggs for vaccine development and production. This will result in improved quality, production costs and viral yields for vaccine manufacturers leading to cost and availability benefits for health service providers for immunisation programmes to protect the health and lives of populations whilst enabling a rapid response to Global pandemic demands. There is exceptionally strong market pull for our innovative disruptive technology, and the increasing use of vaccines to support global demand for quality eggs estimated CAGR of 8.8% and market value of USD 1.89Bn by 2022.

OPPORTUNITY: Over 1bn fertilised specific pathogen free (SPF) chicken eggs are used annually in vaccine manufacture, servicing a vaccine market size estimated to be worth €48bn by 2021 with an AGR of 8.3%.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More